Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M2 Muscarinic Acetylcholine Receptor

Journal of Medicinal Chemistry

Volumn 60, Issue 8, 2017, Pages 3314-3334

  Pegoli, Andrea ^a   She, Xueke ^a   Wifling, David ^a   Hübner, Harald ^b   Bernhardt, Günther ^a   Gmeiner, Peter ^b   Keller, Max ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; DIBENZODIAZEPINONE ANTAGONIST; ISOPHTHALIC ACID; MUSCARINIC M2 RECEPTOR; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; RADIOISOTOPE;

ALKYLATION; ARTICLE; CELL FREE SYSTEM; CRYSTAL STRUCTURE; DEBENZYLATION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INCUBATION TIME; ISOTOPE LABELING; MASS SPECTROMETRY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; RECEPTOR BINDING ASSAY; RECEPTOR OCCUPANCY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCATCHARD PLOT; SLOPE FACTOR; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; METABOLISM;

BENZODIAZEPINONES; BINDING SITES; MOLECULAR DYNAMICS SIMULATION; MUSCARINIC ANTAGONISTS; RADIOISOTOPES; RECEPTOR, MUSCARINIC M2;

EID: 85018409442     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01892     Document Type: Article

References (81)

1. Eglen, R. M. Overview of muscarinic receptor subtypes Handb. Exp. Pharmacol. 2012, 208, 3-28 10.1007/978-3-642-23274-9_1
2. Eglen, R. M.; Choppin, A.; Watson, N. Therapeutic opportunities from muscarinic receptor research Trends Pharmacol. Sci. 2001, 22, 409-414 10.1016/S0165-6147(00)01737-5
3. Sheardown, M. J. Muscarinic M1receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer’s disease Expert Opin. Ther. Pat. 2002, 12, 863-870 10.1517/13543776.12.6.863
4. Clader, J. W.; Wang, Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer’s disease Curr. Pharm. Des. 2005, 11, 3353-3361 10.2174/138161205774370762
5. Citron, M. Alzheimer’s disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387-398 10.1038/nrd2896
6. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54 10.1038/nrd2760
7. Kruse, A. C.; Hu, J.; Pan, A. C.; Arlow, D. H.; Rosenbaum, D. M.; Rosemond, E.; Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, B. K. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 2012, 482, 552-556 10.1038/nature10867
8. Birdsall, N. J. M.; Lazareno, S. Allosterism at muscarinic receptors: ligands and mechanisms Mini-Rev. Med. Chem. 2005, 5, 523-543 10.2174/1389557054023251
9. Conn, P. J.; Jones, C. K.; Lindsley, C. W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 2009, 30, 148-155 10.1016/j.tips.2008.12.002
10. Clark, A. L.; Mitchelson, F. The inhibitory effect of gallamine on muscarinic receptors Br. J. Pharmacol. 1976, 58, 323-331 10.1111/j.1476-5381.1976.tb07708.x
11. Luellmann, H.; Ohnesorge, F. K.; Schauwecker, G. C.; Wassermann, O. Inhibition of the actions of carbachol and DFP [disopropyl phosphorofluoridate] on guinea pig isolated atria by alkane-bis-ammonium compounds Eur. J. Pharmacol. 1969, 6, 241-247 10.1016/0014-2999(69)90181-2
12. Croy, C. H.; Schober, D. A.; Xiao, H.; Quets, A.; Christopoulos, A.; Felder, C. C. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M2 and M4 receptors Mol. Pharmacol. 2014, 86, 106-115 10.1124/mol.114.091751
13. Schober, D. A.; Croy, C. H.; Xiao, H.; Christopoulos, A.; Felder, C. C. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites Mol. Pharmacol. 2014, 86, 116-123 10.1124/mol.114.091785
14. Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: novel opportunities for drug development Nat. Rev. Drug Discovery 2014, 13, 549-560 10.1038/nrd4295
15. Trankle, C.; Weyand, O.; Voigtlander, U.; Mynett, A.; Lazareno, S.; Birdsall, N. J. M.; Mohr, K. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors Mol. Pharmacol. 2003, 64, 180-190 10.1124/mol.64.1.180
16. Christopoulos, A.; Changeux, J. P.; Catterall, W. A.; Fabbro, D.; Burris, T. P.; Cidlowski, J. A.; Olsen, R. W.; Peters, J. A.; Neubig, R. R.; Pin, J. P.; Sexton, P. M.; Kenakin, T. P.; Ehlert, F. J.; Spedding, M.; Langmead, C. J. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands Pharmacol. Rev. 2014, 66, 918-947 10.1124/pr.114.008862
17. Antony, J.; Kellershohn, K.; Mohr-Andrae, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Traenkle, C.; Kostenis, E.; Christopoulos, A.; Hoeltje, H.-D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 2009, 23, 442-450 10.1096/fj.08-114751
18. De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Trankle, C.; Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med. Res. Rev. 2010, 30, 463-549 10.1002/med.20166
19. Valant, C.; Lane, J. R.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178 10.1146/annurev-pharmtox-010611-134514
20. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66 10.1016/j.tips.2012.10.003
21. Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure Mol. Pharmacol. 2014, 86, 463-478 10.1124/mol.114.094342
22. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 2012, 482, 547-551 10.1038/nature10753
23. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-106 10.1038/nature12735
24. Thal, D. M.; Sun, B.; Feng, D.; Nawaratne, V.; Leach, K.; Felder, C. C.; Bures, M. G.; Evans, D. A.; Weis, W. I.; Bachhawat, P.; Kobilka, T. S.; Sexton, P. M.; Kobilka, B. K.; Christopoulos, A. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors Nature 2016, 531, 335-340 10.1038/nature17188
25. Mohr, M.; Heller, E.; Ataie, A.; Mohr, K.; Holzgrabe, U. Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84 J. Med. Chem. 2004, 47, 3324-3327 10.1021/jm031095t
26. Disingrini, T.; Muth, M.; Dallanoce, C.; Barocelli, E.; Bertoni, S.; Kellershohn, K.; Mohr, K.; De Amici, M.; Holzgrabe, U. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J. Med. Chem. 2006, 49, 366-372 10.1021/jm050769s
27. Steinfeld, T.; Mammen, M.; Smith, J. A.; Wilson, R. D.; Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor Mol. Pharmacol. 2007, 72, 291-302 10.1124/mol.106.033746
28. Bock, A.; Mohr, K. Dualsteric GPCR targeting and functional selectivity: the paradigmatic M(2) muscarinic acetylcholine receptor Drug Discovery Today: Technol. 2013, 10, e245-252 10.1016/j.ddtec.2012.12.003
29. Schmitz, J.; van der Mey, D.; Bermudez, M.; Klockner, J.; Schrage, R.; Kostenis, E.; Trankle, C.; Wolber, G.; Mohr, K.; Holzgrabe, U. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity J. Med. Chem. 2014, 57, 6739-6750 10.1021/jm500790x
30. Trankle, C.; Andresen, I.; Lambrecht, G.; Mohr, K. M2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site Mol. Pharmacol. 1998, 53, 304-312 10.1124/mol.53.2.304
31. Mitchelson, F. J. The pharmacology of McN-A-343 Pharmacol. Ther. 2012, 135, 216-245 10.1016/j.pharmthera.2012.05.008
32. Keller, M.; Trankle, C.; She, X.; Pegoli, A.; Bernhardt, G.; Buschauer, A.; Read, R. W. M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding Bioorg. Med. Chem. 2015, 23, 3970-3990 10.1016/j.bmc.2015.01.015
33. Eberlein, W. G.; Engel, W.; Mihm, G.; Rudolf, K.; Wetzel, B.; Entzeroth, M.; Mayer, N.; Doods, H. N. Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics Trends Pharmacol. Sci. 1989, Suppl ) 50-54
34. Dimick, S. M.; Powell, S. C.; McMahon, S. A.; Moothoo, D. N.; Naismith, J. H.; Toone, E. J. On the meaning of affinity: cluster glycoside effects and concanavalin A J. Am. Chem. Soc. 1999, 121, 10286-10296 10.1021/ja991729e
35. Park, J.; Wang, Z. U.; Sun, L.-B.; Chen, Y.-P.; Zhou, H.-C. Introduction of functionalized mesopores to metal-organic frameworks via metal-ligand-fragment coassembly J. Am. Chem. Soc. 2012, 134, 20110-20116 10.1021/ja3085884
36. Bailey, P. D.; Beard, M. A.; Dang, H. P. T.; Phillips, T. R.; Price, R. A.; Whittaker, J. H. Debenzylation using catalytic hydrogenolysis in trifluoroethanol, and the total synthesis of (−)-raumacline Tetrahedron Lett. 2008, 49, 2150-2153 10.1016/j.tetlet.2008.01.104
37. Copeland, R. A. Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 2011, 3, 1491-1501 10.4155/fmc.11.112
38. Vauquelin, G. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time Naunyn-Schmiedeberg's Arch. Pharmacol. 2013, 386, 949-962 10.1007/s00210-013-0881-0
39. Hulme, E. C.; Trevethick, M. A. Ligand binding assays at equilibrium: validation and interpretation Br. J. Pharmacol. 2010, 161, 1219-1237 10.1111/j.1476-5381.2009.00604.x
40. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing Pharmacol. Rev. 2002, 54, 323-374 10.1124/pr.54.2.323
41. Dei, S.; Bellucci, C.; Buccioni, M.; Ferraroni, M.; Guandalini, L.; Manetti, D.; Martini, E.; Marucci, G.; Matucci, R.; Nesi, M.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure J. Med. Chem. 2007, 50, 1409-1413 10.1021/jm061374r
42. Jakubik, J.; El-Fakahany, E. E.; Dolezal, V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors Mol. Pharmacol. 2006, 70, 656-666 10.1124/mol.106.023762
43. Kenakin, T. P. A Pharmacology Primer: Theory, Applications, and Methods, 3rd ed.; Elsevier Academic Press: Burlington, 2009.
44. Hedlund, P. B.; Carson, M. J.; Sutcliffe, J. G.; Thomas, E. A. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors Biochem. Pharmacol. 1999, 58, 1807-1813 10.1016/S0006-2952(99)00274-9
45. Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Overview of receptor allosterism. In Current Protocols in Pharmacology; Wiley: Hoboken, NJ, 2010; Chapter 1, Unit 1.21, DOI 10.1002/0471141755.ph0121s51.
46. Suga, H.; Ehlert, F. J. Effects of asparagine mutagenesis of conserved aspartic acids in helix 2 (D2.50) and 3 (D3.32) of M1-M4 muscarinic receptors on the irreversible binding of nitrogen mustard analogs of acetylcholine and McN-A-343 Biochemistry 2013, 52, 4914-4928 10.1021/bi4003698
47. 1R antagonists as tracers for PET imaging of mammary carcinoma ACS Med. Chem. Lett. 2017, 8, 304-309 10.1021/acsmedchemlett.6b00467
48. Cohen, V. I.; Baumgold, J.; Jin, B.; De La Cruz, R.; Rzeszotarski, W. J.; Reba, R. C. Synthesis and structure-activity relationship of some 5-[[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro-5H-benzo[b,e][1,4]diazepin-11-ones as M2-selective antimuscarinics J. Med. Chem. 1993, 36, 162-165 10.1021/jm00053a021
49. Kane, B. E.; Grant, M. K. O.; El-Fakahany, E. E.; Ferguson, D. M. Synthesis and evaluation of xanomeline analogs-Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor Bioorg. Med. Chem. 2008, 16, 1376-1392 10.1016/j.bmc.2007.10.058
50. Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C. R.; Sorba, G.; Canonico, P. L.; Genazzani, A. A.; Tron, G. C.; Billington, R. A. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage ChemMedChem 2008, 3, 771-779 10.1002/cmdc.200700311
51. Ruger, C.; Rohnert, H.; Lohmann, D. New derivatives of 5,10-dihydro-11H-dibenzo[b, e][1,4]diazepine-11-ones with anticholinergic activity Pharmazie 1990, 45, 555-559
52. Keller, M.; Kuhn, K. K.; Einsiedel, J.; Hubner, H.; Biselli, S.; Mollereau, C.; Wifling, D.; Svobodova, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P. M.; Gmeiner, P.; Buschauer, A. Mimicking of arginine by functionalized N (omega)-carbamoylated arginine as a new broadly applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, neuropeptide FF, and neurotensin receptor ligands as examples J. Med. Chem. 2016, 59, 1925-1945 10.1021/acs.jmedchem.5b01495
53. Hübner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D3 subtype J. Med. Chem. 2000, 43, 756-762 10.1021/jm991098z
54. Conklin, B. R.; Farfel, Z.; Lustig, K. D.; Julius, D.; Bourne, H. R. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha Nature 1993, 363, 274-276 10.1038/363274a0
55. Huang, W.; Manglik, A.; Venkatakrishnan, A. J.; Laeremans, T.; Feinberg, E. N.; Sanborn, A. L.; Kato, H. E.; Livingston, K. E.; Thorsen, T. S.; Kling, R. C.; Granier, S.; Gmeiner, P.; Husbands, S. M.; Traynor, J. R.; Weis, W. I.; Steyaert, J.; Dror, R. O.; Kobilka, B. K. Structural insights into micro-opioid receptor activation Nature 2015, 524, 315-321 10.1038/nature14886
56. Lomize, M. A.; Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. OPM: orientations of proteins in membranes database Bioinformatics 2006, 22, 623-625 10.1093/bioinformatics/btk023
57. Jo, S.; Kim, T.; Im, W. Automated builder and database of protein/membrane complexes for molecular dynamics simulations PLoS One 2007, 2, e880 10.1371/journal.pone.0000880
58. Jo, S.; Kim, T.; Iyer, V. G.; Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM J. Comput. Chem. 2008, 29, 1859-1865 10.1002/jcc.20945
59. Brooks, B. R.; Brooks, C. L., 3rd; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: the biomolecular simulation program J. Comput. Chem. 2009, 30, 1545-1614 10.1002/jcc.21287
60. Wu, E. L.; Cheng, X.; Jo, S.; Rui, H.; Song, K. C.; Davila-Contreras, E. M.; Qi, Y.; Lee, J.; Monje-Galvan, V.; Venable, R. M.; Klauda, J. B.; Im, W. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations J. Comput. Chem. 2014, 35, 1997-2004 10.1002/jcc.23702
61. Lee, J.; Cheng, X.; Swails, J. M.; Yeom, M. S.; Eastman, P. K.; Lemkul, J. A.; Wei, S.; Buckner, J.; Jeong, J. C.; Qi, Y.; Jo, S.; Pande, V. S.; Case, D. A.; Brooks, C. L., 3rd; MacKerell, A. D., Jr.; Klauda, J. B.; Im, W. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field J. Chem. Theory Comput. 2016, 12, 405-413 10.1021/acs.jctc.5b00935
62. MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 1998, 102, 3586-3616 10.1021/jp973084f
63. Mackerell, A. D., Jr.; Feig, M.; Brooks, C. L., 3rd Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations J. Comput. Chem. 2004, 25, 1400-1415 10.1002/jcc.20065
64. Best, R. B.; Zhu, X.; Shim, J.; Lopes, P. E.; Mittal, J.; Feig, M.; Mackerell, A. D., Jr. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles J. Chem. Theory Comput. 2012, 8, 3257-3273 10.1021/ct300400x
65. Klauda, J. B.; Venable, R. M.; Freites, J. A.; O’Connor, J. W.; Tobias, D. J.; Mondragon-Ramirez, C.; Vorobyov, I.; MacKerell, A. D., Jr.; Pastor, R. W. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types J. Phys. Chem. B 2010, 114, 7830-7843 10.1021/jp101759q
66. Beglov, D.; Roux, B. Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations J. Chem. Phys. 1994, 100, 9050-9063 10.1063/1.466711
67. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935 10.1063/1.445869
68. Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 2010, 31, 671-690 10.1002/jcc.21367
69. Vanommeslaeghe, K.; MacKerell, A. D., Jr. Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing J. Chem. Inf. Model. 2012, 52, 3144-3154 10.1021/ci300363c
70. Vanommeslaeghe, K.; Raman, E. P.; MacKerell, A. D., Jr. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges J. Chem. Inf. Model. 2012, 52, 3155-3168 10.1021/ci3003649
71. Yu, W.; He, X.; Vanommeslaeghe, K.; MacKerell, A. D., Jr. Extension of the CHARMM General Force Field to sulfonyl-containing compounds and its utility in biomolecular simulations J. Comput. Chem. 2012, 33, 2451-2468 10.1002/jcc.23067
72. Salomon-Ferrer, R.; Gotz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. explicit solvent particle mesh ewald J. Chem. Theory Comput. 2013, 9, 3878-3888 10.1021/ct400314y
73. Le Grand, S.; Götz, A. W.; Walker, R. C. SPFP: Speed without compromise-A mixed precision model for GPU accelerated molecular dynamics simulations Comput. Phys. Commun. 2013, 184, 374-380 10.1016/j.cpc.2012.09.022
74. Uberuaga, B. P.; Anghel, M.; Voter, A. F. Synchronization of trajectories in canonical molecular-dynamics simulations: observation, explanation, and exploitation J. Chem. Phys. 2004, 120, 6363-6374 10.1063/1.1667473
75. Sindhikara, D. J.; Kim, S.; Voter, A. F.; Roitberg, A. E. Bad seeds sprout perilous dynamics: stochastic thermostat induced trajectory synchronization in biomolecules J. Chem. Theory Comput. 2009, 5, 1624-1631 10.1021/ct800573m
76. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath J. Chem. Phys. 1984, 81, 3684-3690 10.1063/1.448118
77. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092 10.1063/1.464397
78. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-341 10.1016/0021-9991(77)90098-5
79. Sokal, R. R.; Michener, C. D. A statistical method for evaluating systematic relationships Univ. Kansas Sci. Bull. 1958, 28, 1409-1438
80. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612 10.1002/jcc.20084
81. Cheng, Y.-C.; Prusoff, W. H. Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction Biochem. Pharmacol. 1973, 22, 3099-3108 10.1016/0006-2952(73)90196-2